Melinta Therapeutics

Overview

• Industrypharmaceutical industry¹
• HeadquartersNew Haven¹
• Websitewww.rib-x.com

See how the biggest companies compare on our leaderboards

Melinta Therapeutics is an American biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. The company is located in Parsippany, New Jersey.²

Corporate structure

Melinta Therapeutics is part of a group headed by CorMedix Inc.. 7 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC. Each entity in the chart links to its source.

Products and brands

• broad-spectrum antibiotic

Listed on Wikidata.¹

Timeline

1. 2000Founded Founded¹

Calendar

Drug trials and FDA: recently

1. Nov 20, 2025Phase 2 trial completed Phase 2 trial of Orbactiv and Kimyrsa in Acute Bacterial Skin and Skin Structure Infection: primary completion Nov 20, 2025, no results posted yet (ClinicalTrials.gov NCT05599295).³

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Federal awards

Obligated amounts from USAspending.gov⁴, by calendar year, 2013–2025, for 2 registered units, including subsidiaries under the same parent. Obligations are what agencies committed, not always what was paid out. Contracts pay for goods and services; grants, loans and direct payments are assistance. Loans are charted at the face value of the loans listed here. An award’s amount below is its lifetime total, and some began before the years charted.

Largest contracts

1. May 24, 2013$52.5M from Office of Assistant Secretary for Preparedness and Response: Cempra - solithromycin (cem-101) for civilian use and broad bioterror threat medical countermeasures.⁵ To CEMPRA PHARMACEUTICALS, INC. Award HHSO100201300009C
2. Jul 6, 2023$47.5M from Office of Assistant Secretary for Preparedness and Response: Advance the development of two antibiotics for use in the pediatric population for the treatment of serious bacterial infections where multi⁶ To MELINTA THERAPEUTICS, LLC Award 75A50123C00022

Links

• Websitewww.rib-x.com¹
• X (Twitter)x.com/melintatx¹
• WikipediaMelinta Therapeutics
• WikidataQ7322194